In West Germany, Biotechnology Faces Its Day Of Reckoning

The Bundestag is about to hand down a decision whether biotech work can continue FRANKFURT--It's not often that a country grapples publicly with its future in a key area of science and technology. But that's what is happening now in West Germany. Later this month, a plenary session of the Bundestag (the nation's parliament) will begin debating the report of a parliamentary commission, entitled Prospects and Risks of Genetic Engineering, which recommends a total ban on the release of genetical

Written byDede Williams
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

FRANKFURT--It's not often that a country grapples publicly with its future in a key area of science and technology. But that's what is happening now in West Germany. Later this month, a plenary session of the Bundestag (the nation's parliament) will begin debating the report of a parliamentary commission, entitled Prospects and Risks of Genetic Engineering, which recommends a total ban on the release of genetically manipulated microorganisms into the environment. The results of this debate are likely to be formalized in West Germany's first comprehensive law on recombinant DNA activities, expected to be passed by the end of May.

To say that West Germans are anxiously awaiting the law would be an understatement. Scientists, naturally, are worried that the government will make it impossible to continue their experiments. Restrictive regulations have already turned West Germany into one of the most difficult places in the world to do molecular biology. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies